Molecular Partners AG (MOLN)
MOLN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1745114/000174511426000009/0001745114-26-000009-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31. Converted from CHF at 0.8334 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | MOLN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Switzerland |
| IPO year | 2021 |
| SEC CIK | 0001745114 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | V8 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$74.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Reported in CHF; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2025-04-11 |
| Latest annual report | 20-F | 2026-03-12 |
| Latest quarterly / interim | 6-K | 2026-08-25 |
Source: SEC EDGAR submissions feed, 120 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics Inc. | $0.5638 | -3.64% | $137.3M |
| AVXL | Anavex Life Sciences Corp. | $1.48 | -1.99% | $137.2M |
| VYGR | Voyager Therapeutics Inc. | $2.15 | -5.29% | $132.5M |
| ABOS | Acumen Pharmaceuticals Inc. | $1.81 | -10.15% | $131.3M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $1.20 | +1.70% | $144.8M |
| CMPX | Compass Therapeutics Inc. | $0.8570 | -8.59% | $154.3M |
| TARA | Protara Therapeutics Inc. | $2.62 | -5.42% | $154.8M |
| TNYA | Tenaya Therapeutics Inc. | $0.5210 | -7.87% | $116.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier